94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
REVIEW article
Front. Pharmacol.
Sec. Pharmacology of Anti-Cancer Drugs
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1538601
The Multiple Biological Activities of Hyperoside: From Molecular Mechanisms to Therapeutic Perspectives in Neoplastic and Non-Neoplastic Diseases
Provisionally accepted
Weisong Zhang 1
Wang Rui 1
Rongqi Guo 1
ZhongQuan Yi 2
Yihao Wang 1* Hao Wang 1* Yangyang Li 1*
Xia Li 2* Jianxiang Song 1,2*- 1 Nantong University, Nantong, China
- 2 Yancheng Third People's Hospital, Yancheng, China
In recent years, hyperoside (quercetin 3-O-β-D-galactopyranoside) has garnered significant attention due to its diverse biological effects, which include vasoprotective, antioxidant, anti-inflammatory, and anti-tumor properties. Notably, hyperoside has shown remarkable potential in cancer therapy by targeting multiple mechanisms; it induces apoptosis, inhibits proliferation, blocks angiogenesis, and reduces the metastatic potential of cancer cells. Furthermore, hyperoside enhances the sensitivity of cancer cells to chemotherapy by modulating key signaling pathways. Beyond neoplastic diseases, hyperoside also presents promising therapeutic applications in managing non-cancerous conditions such as diabetes, Alzheimer's disease, and pulmonary fibrosis. This review comprehensively examines the molecular mechanisms underlying hyperoside's anti-cancer effects and highlights its role in the treatment of cancers, including lung and colorectal cancers. Additionally, it explores the latest research on hyperoside's potential in addressing non-neoplastic conditions, such as pulmonary fibrosis, diabetes, and Parkinson's disease. By summarizing current findings, this review underscores the unique therapeutic value of hyperoside and its potential as a multifunctional treatment in both neoplastic and non-neoplastic contexts.
Keywords: Hyperoside, tumor, antioxidant, anti-inflammatory, signaling pathway, Non-neoplastic diseases
Received: 03 Dec 2024; Accepted: 13 Feb 2025.
Copyright: © 2025 Zhang, Rui, Guo, Yi, Wang, Wang, Li, Li and Song. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Yihao Wang, Nantong University, Nantong, China
Hao Wang, Nantong University, Nantong, China
Yangyang Li, Nantong University, Nantong, China
Xia Li, Yancheng Third People's Hospital, Yancheng, China
Jianxiang Song, Nantong University, Nantong, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.